Drenth JP - Search Results

1

Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study.

van Munster KN, Mol B, Goet JC, van Munster SN, Weersma RK, de Vries AC, van der Meer AJ, Inderson A, Drenth JP, van Erpecum KJ, Boonstra K, Beuers U, Dijkgraaf MGW, Ponsioen CY; EpiPSC2 Study Group. van Munster KN, et al. Among authors: drenth jp. Liver Int. 2023 Mar;43(3):639-648. doi: 10.1111/liv.15471. Epub 2022 Nov 15. Liver Int. 2023. PMID: 36328957

2

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.

Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Hoevenaren IA, et al. Among authors: drenth jp. Liver Int. 2008 Feb;28(2):264-70. doi: 10.1111/j.1478-3231.2007.01595.x. Epub 2007 Oct 9. Liver Int. 2008. PMID: 17927714

3

Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease.

Waanders E, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP. Waanders E, et al. Among authors: drenth jp. Liver Int. 2009 Oct;29(9):1389-95. doi: 10.1111/j.1478-3231.2009.02055.x. Epub 2009 Jun 3. Liver Int. 2009. PMID: 19515221

4

No beneficial effects of amantadine in treatment of chronic hepatitis C patients.

van Soest H, van der Schaar PJ, Koek GH, de Vries RA, van Ooteghem NA, van Hoek B, Drenth JP, Vrolijk JM, Lieverse RJ, Houben P, van der Sluys Veer A, Siersema PD, Schipper ME, van Erpecum KJ, Boland GJ. van Soest H, et al. Among authors: drenth jp. Dig Liver Dis. 2010 Jul;42(7):496-502. doi: 10.1016/j.dld.2009.10.006. Epub 2009 Dec 16. Dig Liver Dis. 2010. PMID: 20018575 Clinical Trial.

5

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Van Keimpema L, et al. Among authors: drenth jp. Liver Int. 2011 Jan;31(1):92-8. doi: 10.1111/j.1478-3231.2010.02247.x. Liver Int. 2011. PMID: 20408955

6

Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.

Van Vlerken LG, Van Soest H, Janssen MP, Boland GJ, Drenth JP, Burger DM, Siersema PD, Van Erpecum KJ. Van Vlerken LG, et al. Among authors: drenth jp. Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1308-15. doi: 10.1097/MEG.0b013e32833e784d. Eur J Gastroenterol Hepatol. 2010. PMID: 20729740 Clinical Trial.

7

Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Boonstra K, van Erpecum KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BJ, Tuynman HA, Beuers U, Ponsioen CY. Boonstra K, et al. Among authors: drenth jp. Inflamm Bowel Dis. 2012 Dec;18(12):2270-6. doi: 10.1002/ibd.22938. Epub 2012 Mar 8. Inflamm Bowel Dis. 2012. PMID: 22407885

8

Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, Beuers U, van Buuren HR, de Man RA, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Mulder CJ, van Nieuwkerk KM, Bouma G; Dutch Autoimmune Hepatitis Working Group. van Gerven NM, et al. Among authors: drenth jp. J Hepatol. 2013 Jan;58(1):141-7. doi: 10.1016/j.jhep.2012.09.009. Epub 2012 Sep 16. J Hepatol. 2013. PMID: 22989569

9

Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis.

van Gerven NM, de Boer YS, Zwiers A, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Bouma G; Dutch Autoimmune Hepatitis Study group. van Gerven NM, et al. Among authors: drenth jp. Liver Int. 2013 Aug;33(7):1039-43. doi: 10.1111/liv.12157. Epub 2013 Mar 31. Liver Int. 2013. PMID: 23551963

10

Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome.

van Vlerken LG, de Kanter CT, Boland GJ, van Loon AM, van Soest H, Koek GH, Drenth JP, Siersema PD, van Erpecum KJ, Burger DM. van Vlerken LG, et al. Among authors: drenth jp. Ther Drug Monit. 2013 Aug;35(4):546-51. doi: 10.1097/FTD.0b013e31828a9fbf. Ther Drug Monit. 2013. PMID: 23851908 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

642 results

Search Page